Moreover, clinical trials indicate that anti-PD-1/PD-L1 combined with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade exerts a synergistic antitumor effect in melanoma and lung cancer (Chae et al., 2018). This evidence concerns the gene CTLA4 and lung carcinoma.